Immunocore Holdings PLC Sustainability Reports
Immunocore Holdings PLC is a commercial-stage biotechnology company that develops a novel class of T cell receptor bispecific immunotherapies called ImmTAX. The company's therapies are designed to treat a wide range of diseases, including cancer, autoimmune, and infectious diseases.
Sector: Professional & technical services
Country: United Kingdom
Exchange: Nasdaq
LEI: 213800IUE3DFS84BVN18
FIGI: BBG00YYCXG54
6 reports from 2021 to 2025
- Immunocore Holdings PLC 2025 UK Gender Pay Gap Report
- Immunocore Holdings PLC 2025 Annual Report
- Immunocore Holdings PLC 2024 Annual Report and Consolidated Financial Statements
- Immunocore Holdings PLC 2023 Annual Report and Consolidated Financial Statements
- Immunocore Holdings PLC 2022 Annual Report and Consolidated Financial Statements
